Research Reports

Key takeaways

Revenue was $40.0K, consistent with clinical-stage status focused on preclinical and clinical studies rather than commercial sales.

Operating income was -$58.2M, driven by significant operating losses since inception as the company develops its technology and intellectual property portfolio.

Net income was -$62.1M with diluted EPS of $-3.20, as prior and ongoing losses adversely affect stockholders' deficit and working capital.

Net cash used in operating activities was -$20.4M, funded through common stock and debt issuances from related and third parties given the lack of profitability.

General and administrative expenses increased, primarily from investor awareness marketing, higher headcount compensation, rent, and travel as operations scale.

Full analysis

Neonc Technologies Holdings, Inc. (NTHI) continued its clinical-stage focus in FY2025, generating just $40.0K in revenue while posting an operating loss of -$58.2M and net loss of -$62.1M, with diluted EPS at $-3.20. These results stem from the company's inception-stage priorities: organizing operations, raising capital, developing technology, building an intellectual property portfolio, and advancing preclinical and clinical studies including manufacturing. Since inception, Neonc has incurred significant operating losses, funding activities through common stock sales and debt from related and third parties, which explains the wide gap between minimal revenue and substantial expenses.

NTHI · Neonc Technologies Holdings, Inc.

Summary

Key takeaways

Full analysis